|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Supplemental Table 1. Adverse outcomes assessed.** | | | | | |
| Outcome | | Risk Interval (days)a | Comparison intervala | Clear period requiredb | ICD9 codes |
| Primary outcomes | |  |  |  |  |
|  | Acute inpatient asthma stay or Emergency Dept. asthma encounterc | 1 to 14 | 29 to 42 | None | 493.xx |
|  | Outpatient asthma visit | 1 to 14 | 29 to 42 | None | 493.xx |
| Secondary outcomesd | |  |  |  |  |
|  | Afebrile seizures/ nonspecific paroxysmal spell | 1 to 7 | 29 to 42 | 60 days | 780.3, 780.39 |
|  | Bell's palsy | 1 to 14 | 29 to 42 | 60 days | 351.0x |
|  | Febrile seizure | 0 to ≤2 | 29 to 42 | 60 days | 780.31, 780.32 |
|  | Epistaxis | 1 to 7 | 29 to 42 | 60 days | 784.7x |
|  | Fever | 1 to ≤2 | 29 to 42 | 60 days | 780.6x |
|  | Gastrointestinal disorders | 1 to 7 | 29 to 42 | 60 days | 003.0x, 008.45, 008.8x, 009.0x, 009.1x, 009.2x, 009.3x, 488.19, 488.89, 558.9x, 564.1x, 564.5x, 787.01,787.91 |
|  | Migraine | 1 to 7 | 29 to 42 | 60 days | 346.xx |
|  | Otitis media | 1 to 7 | 29 to 42 | 60 days | 381.xx |
|  | Sinusitis | 1 to 7 | 29 to 42 | 60 days | 461.xx, 461.0x, 461.1x, 461.2x, 461.3x, 461.8x, 461.9x |
|  | Any non-asthma outpatient visite | 1 to 14 | 29 to 42 | None | na |
| a Intervals refer to the number of days after immunization with LAIV or IIV. In all models, events were counted only if they occurred during the risk or comparison interval. LAIV: live attenuated influenza vaccine; IIV: inactivated influenza vaccine. | | | | | |
| b Event was only counted if there was not another event of the same kind in the prior (x) days, where "x" is the clear period required. | | | | | |
| c Sensitivity analyses were also run using an alternative risk interval (7 to <=28 days) and comparison interval (29 to <=50 days). | | | | | |
| d For all these events except "any non-asthma outpatient visit" diagnosis could be in any setting. | | | | | |
| e Non-asthma visits were not considered to be adverse outcomes, but were assessed as a negative control, since we did not expect the differences between IIV and LAIV with respect to these visits. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Table 2. Summary of chart review results.** | | | | | | |
|  | IIV |  | LAIV | | | |
|  |  |  | Asthma Type | | | |
| Characteristic | Remote history of asthma only |  | Active, persistent | Active, not persistent | Remote history of asthma only | All asthma types |
| Number of immunizations | 82,198 |  | 14,039 | 16,160 | 26,627 | 56,826 |
| Number of outpatient adverse events prior to chart review confirmation |  |  |  |  |  |  |
| 1 to 14 days after immunization | 300 |  | 201 | 120 | 40 | 361 |
| 29 to 42 days after immunization | 272 |  | 273 | 145 | 67 | 485 |
| Number of CONFIRMED outpatient adverse events by chart review |  |  |  |  |  |  |
| 1 to 14 days after immunization | 211 |  | 129 | 83 | 30 | 242 |
| 29 to 42 days after immunization | 192 |  | 187 | 112 | 50 | 349 |
| Percent of events confirmed |  |  |  |  |  |  |
| 1 to 14 days after immunization | *70%* |  | *64%* | *69%* | *75%* | *67%* |
| 29 to 42 days after immunization | *71%* |  | *68%* | *77%* | *75%* | *72%* |
| All days in the two intervals | *70%* |  | *67%* | *74%* | *75%* | *70%* |